Drug manufacturer Kala Pharmaceuticals continues to rise by more than 20%, FDA accepts new drug application for its main candidate product KPI-012 | US stocks_Sina Finance_Sina.com

Install the Sina Finance client to receive the most comprehensive market information at the first time→【Download Address】

On Thursday, the stock price of drug manufacturer Kala Pharmaceuticals (KALA.US) continued to rise. As of press time, the stock rose more than 20% to $15.

Kala Pharmaceuticals surged 218% yesterday. The U.S. Food and Drug Administration (FDA) has accepted an investigational new drug application for its lead drug candidate, KPI-012, for a rare disease of the eye, the company said Tuesday.

Editor in charge: Guo Mingyu